This HTML5 document contains 200 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/kegg-drug/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/iuphar/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/drugbank/
n13http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n34http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/guide-to-pharmacology/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/national-drug-code-directory/
n20http://linked.opendata.cz/resource/drugbank/mixture/
n17http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/chemspider/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n21http://www.rxlist.com/cgi/generic/
n14http://linked.opendata.cz/resource/drugbank/patent/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n33http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/pharmgkb/
n10http://www.drugs.com/cdi/
n12http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/bindingdb/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00555/identifier/pubchem-compound/
n5http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00555
rdf:type
n3:Drug
n3:description
Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. The exact way lamotrigine works is unknown. [Wikipedia]
n3:dosage
n15:271B4647-363D-11E5-9242-09173F13E4C5 n15:271B4648-363D-11E5-9242-09173F13E4C5 n15:271B4649-363D-11E5-9242-09173F13E4C5 n15:271B464A-363D-11E5-9242-09173F13E4C5 n15:271B4643-363D-11E5-9242-09173F13E4C5 n15:271B4644-363D-11E5-9242-09173F13E4C5 n15:271B4645-363D-11E5-9242-09173F13E4C5 n15:271B4646-363D-11E5-9242-09173F13E4C5 n15:271B464B-363D-11E5-9242-09173F13E4C5 n15:271B4637-363D-11E5-9242-09173F13E4C5 n15:271B4638-363D-11E5-9242-09173F13E4C5 n15:271B4639-363D-11E5-9242-09173F13E4C5 n15:271B463A-363D-11E5-9242-09173F13E4C5 n15:271B4633-363D-11E5-9242-09173F13E4C5 n15:271B4634-363D-11E5-9242-09173F13E4C5 n15:271B4635-363D-11E5-9242-09173F13E4C5 n15:271B4636-363D-11E5-9242-09173F13E4C5 n15:271B463F-363D-11E5-9242-09173F13E4C5 n15:271B4640-363D-11E5-9242-09173F13E4C5 n15:271B4641-363D-11E5-9242-09173F13E4C5 n15:271B4642-363D-11E5-9242-09173F13E4C5 n15:271B463B-363D-11E5-9242-09173F13E4C5 n15:271B463C-363D-11E5-9242-09173F13E4C5 n15:271B463D-363D-11E5-9242-09173F13E4C5 n15:271B463E-363D-11E5-9242-09173F13E4C5 n15:271B4631-363D-11E5-9242-09173F13E4C5 n15:271B4632-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Backonja M: Neuromodulating drugs for the symptomatic treatment of neuropathic pain. Curr Pain Headache Rep. 2004 Jun;8(3):212-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15115640 # Barbosa L, Berk M, Vorster M: A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003 Apr;64(4):403-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12716240 # Jensen TS: Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6 Suppl A:61-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11888243 # Pappagallo M: Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther. 2003 Oct;25(10):2506-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14667954 # Tehrani SP, Daryaafzoon M, Bakhtiarian A, Ejtemaeemehr S, Sahraei H: The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19579915
n3:group
investigational approved
n3:halfLife
25 +/- 10 hours (healthy individuals); 42.9 hours (chronic renal failure)
n3:indication
For the adjunctive treatment of partial seizures in epilepsy and generalized seizures of Lennox-Gastaut syndrome. Also for the maintenance treatment of bipolar I disorder and depression.
n3:manufacturer
n8:271B45FB-363D-11E5-9242-09173F13E4C5 n8:271B45FC-363D-11E5-9242-09173F13E4C5 n8:271B45F3-363D-11E5-9242-09173F13E4C5 n8:271B4602-363D-11E5-9242-09173F13E4C5 n8:271B4603-363D-11E5-9242-09173F13E4C5 n8:271B45F4-363D-11E5-9242-09173F13E4C5 n8:271B45F7-363D-11E5-9242-09173F13E4C5 n8:271B45F8-363D-11E5-9242-09173F13E4C5 n8:271B45F5-363D-11E5-9242-09173F13E4C5 n8:271B45F6-363D-11E5-9242-09173F13E4C5 n8:271B45FD-363D-11E5-9242-09173F13E4C5 n8:271B45FE-363D-11E5-9242-09173F13E4C5 n8:271B45F9-363D-11E5-9242-09173F13E4C5 n8:271B45FA-363D-11E5-9242-09173F13E4C5 n8:271B4601-363D-11E5-9242-09173F13E4C5 n8:271B4604-363D-11E5-9242-09173F13E4C5 n8:271B45FF-363D-11E5-9242-09173F13E4C5 n8:271B4600-363D-11E5-9242-09173F13E4C5 n8:271B4605-363D-11E5-9242-09173F13E4C5 n8:271B4606-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00555 n22:DB00555
dcterms:title
Lamotrigine
adms:identifier
n7:Lamotrigine n19:46505408 n23:6367 n24:3741 n25:50031299 n26:2622 n27:2622 n28:DB00555 n29:PA450164 n30:3878 n31:D00354 n32:0173-0633-02
n3:mechanismOfAction
One proposed mechanism of action of Lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. <i>in vitro</i> pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels and/or calcium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate). Studies on lamotrigine show binding to sodium channels similar to local anesthetics.
n3:packager
n8:271B45F2-363D-11E5-9242-09173F13E4C5 n8:271B45F0-363D-11E5-9242-09173F13E4C5 n8:271B45F1-363D-11E5-9242-09173F13E4C5 n8:271B45EA-363D-11E5-9242-09173F13E4C5 n8:271B45EF-363D-11E5-9242-09173F13E4C5 n8:271B45E8-363D-11E5-9242-09173F13E4C5 n8:271B45E9-363D-11E5-9242-09173F13E4C5 n8:271B45E7-363D-11E5-9242-09173F13E4C5 n8:271B45EB-363D-11E5-9242-09173F13E4C5 n8:271B45E5-363D-11E5-9242-09173F13E4C5 n8:271B45E6-363D-11E5-9242-09173F13E4C5 n8:271B45E3-363D-11E5-9242-09173F13E4C5 n8:271B45E4-363D-11E5-9242-09173F13E4C5 n8:271B45E1-363D-11E5-9242-09173F13E4C5 n8:271B45E2-363D-11E5-9242-09173F13E4C5 n8:271B45DF-363D-11E5-9242-09173F13E4C5 n8:271B45E0-363D-11E5-9242-09173F13E4C5 n8:271B45DD-363D-11E5-9242-09173F13E4C5 n8:271B45DE-363D-11E5-9242-09173F13E4C5 n8:271B45DB-363D-11E5-9242-09173F13E4C5 n8:271B45DC-363D-11E5-9242-09173F13E4C5 n8:271B45D9-363D-11E5-9242-09173F13E4C5 n8:271B45DA-363D-11E5-9242-09173F13E4C5 n8:271B45D7-363D-11E5-9242-09173F13E4C5 n8:271B45D8-363D-11E5-9242-09173F13E4C5 n8:271B45D5-363D-11E5-9242-09173F13E4C5 n8:271B45D6-363D-11E5-9242-09173F13E4C5 n8:271B45D3-363D-11E5-9242-09173F13E4C5 n8:271B45D4-363D-11E5-9242-09173F13E4C5 n8:271B45D1-363D-11E5-9242-09173F13E4C5 n8:271B45D2-363D-11E5-9242-09173F13E4C5 n8:271B45CF-363D-11E5-9242-09173F13E4C5 n8:271B45D0-363D-11E5-9242-09173F13E4C5 n8:271B45CE-363D-11E5-9242-09173F13E4C5 n8:271B45EE-363D-11E5-9242-09173F13E4C5 n8:271B45EC-363D-11E5-9242-09173F13E4C5 n8:271B45ED-363D-11E5-9242-09173F13E4C5
n3:patent
n14:2277722 n14:5698226
n3:synonym
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine Lamotriginum Lamictal Lamotrigina Lamotrigine
n3:toxicity
LD<sub>50</sub>=250 (mg/kg) (in rat, mice); LD<sub>50</sub>>640 orally (mg/kg) (in rat, mice) (Sawyer). Symptoms of overdose include decreased level of consciousness, coma, delayed heartbeat, increased seizures, lack of coordination, and rolling eyeballs.
n3:volumeOfDistribution
* 0.9 to 1.3 L/kg
n4:hasAHFSCode
n13:28-12-92
n3:foodInteraction
Take without regard to meals.
n3:mixture
n20:271B45CD-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
55%
n3:synthesisReference
Grahame Roy Lee, "Process for the preparation of lamotrigine." U.S. Patent US5925755, issued January, 1981.
n33:hasConcept
n34:M0137818
foaf:page
n10:lamotrigine.html n21:lamotrigine.htm
n3:IUPAC-Name
n12:271B4650-363D-11E5-9242-09173F13E4C5
n3:InChI
n12:271B4656-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n12:271B4655-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n12:271B4652-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n12:271B4653-363D-11E5-9242-09173F13E4C5
n3:SMILES
n12:271B4654-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n12:271B464E-363D-11E5-9242-09173F13E4C5
n3:logP
n12:271B4667-363D-11E5-9242-09173F13E4C5 n12:271B464C-363D-11E5-9242-09173F13E4C5 n12:271B464F-363D-11E5-9242-09173F13E4C5
n3:logS
n12:271B464D-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n5:N03AX09
n3:H-Bond-Acceptor-Count
n12:271B465C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n12:271B465D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n12:271B4657-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n12:271B4658-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n12:271B465A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n12:271B4659-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n12:271B465B-363D-11E5-9242-09173F13E4C5
n3:absorption
98%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
84057-84-1
n3:category
n3:clearance
* Apparent plasma cl=0.44 mL/min/kg [healthy volunteers taking single-dose LAMICTAL] * Apparent plasma cl=0.58 mL/min/kg [healthy volunteers taking multiple-dose LAMICTAL] * Apparent plasma cl=0.30 mL/min/kg [healthy volunteers taking valproate and single-dose LAMICTAL] * Apparent plasma cl=0.18 mL/min/kg [healthy volunteers taking valproate and multiple-dose LAMICTAL] * Apparent plasma cl=1.1 mL/min/kg [Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone plus valproate and single-dose LAMICTAL] * Apparent plasma cl=1.12 mL/min/kg [Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone plus valproate and multiple-dose LAMICTAL]
n3:containedIn
n18:271B4619-363D-11E5-9242-09173F13E4C5 n18:271B461A-363D-11E5-9242-09173F13E4C5 n18:271B4617-363D-11E5-9242-09173F13E4C5 n18:271B4618-363D-11E5-9242-09173F13E4C5 n18:271B4615-363D-11E5-9242-09173F13E4C5 n18:271B4616-363D-11E5-9242-09173F13E4C5 n18:271B4613-363D-11E5-9242-09173F13E4C5 n18:271B4614-363D-11E5-9242-09173F13E4C5 n18:271B4611-363D-11E5-9242-09173F13E4C5 n18:271B4612-363D-11E5-9242-09173F13E4C5 n18:271B460F-363D-11E5-9242-09173F13E4C5 n18:271B4610-363D-11E5-9242-09173F13E4C5 n18:271B460A-363D-11E5-9242-09173F13E4C5 n18:271B460B-363D-11E5-9242-09173F13E4C5 n18:271B4608-363D-11E5-9242-09173F13E4C5 n18:271B4609-363D-11E5-9242-09173F13E4C5 n18:271B4607-363D-11E5-9242-09173F13E4C5 n18:271B462F-363D-11E5-9242-09173F13E4C5 n18:271B4630-363D-11E5-9242-09173F13E4C5 n18:271B462D-363D-11E5-9242-09173F13E4C5 n18:271B462E-363D-11E5-9242-09173F13E4C5 n18:271B462B-363D-11E5-9242-09173F13E4C5 n18:271B462C-363D-11E5-9242-09173F13E4C5 n18:271B4629-363D-11E5-9242-09173F13E4C5 n18:271B462A-363D-11E5-9242-09173F13E4C5 n18:271B4627-363D-11E5-9242-09173F13E4C5 n18:271B4628-363D-11E5-9242-09173F13E4C5 n18:271B4625-363D-11E5-9242-09173F13E4C5 n18:271B4626-363D-11E5-9242-09173F13E4C5 n18:271B4623-363D-11E5-9242-09173F13E4C5 n18:271B4624-363D-11E5-9242-09173F13E4C5 n18:271B4621-363D-11E5-9242-09173F13E4C5 n18:271B4622-363D-11E5-9242-09173F13E4C5 n18:271B461F-363D-11E5-9242-09173F13E4C5 n18:271B4620-363D-11E5-9242-09173F13E4C5 n18:271B461D-363D-11E5-9242-09173F13E4C5 n18:271B461E-363D-11E5-9242-09173F13E4C5 n18:271B461B-363D-11E5-9242-09173F13E4C5 n18:271B461C-363D-11E5-9242-09173F13E4C5 n18:271B460D-363D-11E5-9242-09173F13E4C5 n18:271B460E-363D-11E5-9242-09173F13E4C5 n18:271B460C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n12:271B4662-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n12:271B4664-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n12:271B4665-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n12:271B4666-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n12:271B4661-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n12:271B4660-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n12:271B4663-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n12:271B4651-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n12:271B465E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n12:271B465F-363D-11E5-9242-09173F13E4C5